Published in J Hepatol on June 01, 2005
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
Viral hepatitis in HIV infection. N Engl J Med (2007) 4.18
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS (2008) 2.27
High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther (2011) 2.20
Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis (2009) 2.01
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother (2009) 1.80
Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview. Int J Drug Policy (2007) 1.75
Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort. HIV Med (2008) 1.74
Elevated AST-to-platelet ratio index is associated with increased all-cause mortality among HIV-infected adults in Zambia. Liver Int (2015) 1.68
HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners. Am J Drug Alcohol Abuse (2010) 1.48
Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol (2009) 1.41
Prevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the U.S. Salud Publica Mex (2007) 1.38
Survival trends in critically ill HIV-infected patients in the highly active antiretroviral therapy era. Crit Care (2010) 1.20
Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status. Clin Infect Dis (2008) 1.13
Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts. PLoS One (2009) 1.12
Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS (2009) 1.01
Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol (2009) 0.98
Incidence of hepatitis-C among HIV infected men who have sex with men (MSM) attending a sexual health service: a cohort study. BMC Infect Dis (2011) 0.97
Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C). J Acquir Immune Defic Syndr (2010) 0.97
Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome. Int J Immunogenet (2008) 0.96
Trends in the incidence of primary liver cancer in Central Uganda, 1960-1980 and 1991-2005. Br J Cancer (2009) 0.95
Enhanced IL-10 production in response to hepatitis C virus proteins by peripheral blood mononuclear cells from human immunodeficiency virus-monoinfected individuals. BMC Immunol (2008) 0.93
Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology (2008) 0.92
Porphyromonas gingivalis induces CCR5-dependent transfer of infectious HIV-1 from oral keratinocytes to permissive cells. Retrovirology (2008) 0.92
Interventions to reduce alcohol use among HIV-infected individuals: a review and critique of the literature. Curr HIV/AIDS Rep (2013) 0.92
Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV. Curr HIV/AIDS Rep (2006) 0.91
Drug trafficking routes and hepatitis B in injection drug users, Manipur, India. Emerg Infect Dis (2006) 0.90
Association of HIV infection, hepatitis C virus infection, and metabolic factors with liver stiffness measured by transient elastography. J Infect Dis (2013) 0.90
The Tat protein of human immunodeficiency virus-1 enhances hepatitis C virus replication through interferon gamma-inducible protein-10. BMC Immunol (2012) 0.88
Noncommunicable diseases in HIV infection in low- and middle-income countries: gastrointestinal, hepatic, and nutritional aspects. J Acquir Immune Defic Syndr (2014) 0.87
Hepatitis B and human immunodeficiency virus co-infection. World J Gastroenterol (2014) 0.86
Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems. Addiction (2013) 0.86
Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France). BMC Health Serv Res (2012) 0.85
Role of liver transplantation in human immunodeficiency virus positive patients. World J Gastroenterol (2015) 0.85
Fibrosis progression in paired liver biopsies from HIV/HCV co-infected patients. Hepat Mon (2011) 0.85
Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. World J Hepatol (2016) 0.85
Epidemiological implications of HIV-hepatitis C co-infection in South and Southeast Asia. Curr HIV/AIDS Rep (2014) 0.85
Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: a randomized, controlled trial. PLoS One (2013) 0.84
Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. Can J Gastroenterol (2006) 0.84
Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection. Clin Infect Dis (2012) 0.84
National Trend and Characteristics of Acute Hepatitis C among HIV-Infected Individuals: A Matched Case-Control Study-Taiwan, 2001-2014. PLoS One (2015) 0.84
Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients. World J Hepatol (2012) 0.83
New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy. J Zhejiang Univ Sci B (2012) 0.83
Drinking trajectories among HIV-infected men who have sex with men: a cohort study of United States veterans. Drug Alcohol Depend (2015) 0.82
Hepatitis B and C infection and liver disease trends among human immunodeficiency virus-infected individuals. World J Gastroenterol (2011) 0.82
Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients. J Hepatol (2010) 0.82
Low-level HIV infection of hepatocytes. Virol J (2012) 0.81
Hepatitis B and HIV co-infection is still treated using lamivudine-only antiretroviral therapy combination in Uganda. Afr Health Sci (2015) 0.80
Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection. World J Hepatol (2017) 0.80
Impact of immunodepression and moderate alcohol consumption on coronary and other arterial disease events in an 11-year cohort of HIV-infected patients on antiretroviral therapy. BMJ Open (2012) 0.79
HIV-1 Nef is transferred from expressing T cells to hepatocytic cells through conduits and enhances HCV replication. PLoS One (2014) 0.79
HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. BMC Gastroenterol (2015) 0.79
Evidence of distinct populations of hepatitis C virus in the liver and plasma of patients co-infected with HIV and HCV. J Med Virol (2014) 0.78
Liver Fibrosis in HIV Patients Receiving a Modern cART: Which Factors Play a Role? Medicine (Baltimore) (2015) 0.78
Combination Antiretroviral Therapy Is Associated With Reduction in Liver Fibrosis Scores in HIV-1-Infected Subjects. Medicine (Baltimore) (2016) 0.77
Association of Patients' Geographic Origins with Viral Hepatitis Co-infection Patterns, Spain. Emerg Infect Dis (2011) 0.76
Liver and AIDS mortality in HIV-infected patients. J Hepatol (2005) 0.75
Right Atrial Mass in a Patient With HIV and Hepatitis B: A Case Report. Cardiol Res (2013) 0.75
High Prevalence of Liver Fibrosis in Patients with Human Immunodeficiency Virus Monoinfection and Human Immunodeficiency Virus Hepatitis-B Co-infection as Assessed by Shear Wave Elastography: Study at a Teaching Hospital in Kenya. J Clin Imaging Sci (2016) 0.75
Characterization of HCV NS3 Protease Variants in HCV/HIV Coinfected Patients by Ultra-deep Sequence Analysis: Relationship to Hepatic Fibrosis. J Acquir Immune Defic Syndr (2016) 0.75
Impact of Obliterative Portal Venopathy Associated With Human Immunodeficiency Virus. Medicine (Baltimore) (2016) 0.75
Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents. Pediatr Infect Dis J (2017) 0.75
The role of discrimination in alcohol-related problems in samples of heavy drinking HIV-negative and positive men who have sex with men (MSM). Drug Alcohol Depend (2016) 0.75
HBV infection in untreated HIV-infected adults in Maputo, Mozambique. PLoS One (2017) 0.75
Phosphatidylethanol (PEth) as a Biomarker of Alcohol Consumption in HIV-Infected Young Russian Women: Comparison to Self-Report Assessments of Alcohol Use. AIDS Behav (2017) 0.75
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog (2013) 6.14
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 5.58
Incidence of Dementia over Three Decades in the Framingham Heart Study. N Engl J Med (2016) 5.55
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med (2011) 5.35
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med (2015) 5.30
Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol (2006) 5.25
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Low serum procalcitonin level accurately predicts the absence of bacteremia in adult patients with acute fever. Clin Infect Dis (2002) 4.78
Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS (2003) 4.43
Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol (2009) 4.38
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol (2003) 4.15
Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol (2004) 3.99
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr (2008) 3.44
HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr (2007) 3.38
Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis (2009) 3.28
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis (2013) 3.04
Impact of vital status investigation procedures on estimates of survival in cohorts of HIV-infected patients from Sub-Saharan Africa. J Acquir Immune Defic Syndr (2004) 2.99
Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer (2004) 2.98
Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest (2009) 2.92
Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol (2006) 2.82
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79
HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol (2013) 2.78
Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS (2008) 2.74
Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis (2003) 2.54
Survey of anesthesia-related mortality in France. Anesthesiology (2006) 2.52
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol (2009) 2.51
When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostat (2010) 2.50
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50
Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect (2008) 2.49
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med (2013) 2.49
Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet (2007) 2.37
Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int (2011) 2.28
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS (2008) 2.27
Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis (2009) 2.26
Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS (2002) 2.21
Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS (2008) 2.21
Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS (2006) 2.19
Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med (2010) 2.17
Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14
Long-term cardiovascular mortality after radiotherapy for breast cancer. J Am Coll Cardiol (2011) 2.14
The undiagnosed HIV epidemic in France and its implications for HIV screening strategies. AIDS (2014) 2.04
Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis (2005) 2.03
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (2002) 2.03
CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis (2006) 2.02
Low retention of HIV-infected patients on antiretroviral therapy in 11 clinical centres in West Africa. Trop Med Int Health (2010) 2.00
Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study. J Hepatol (2009) 1.98
Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS (2003) 1.97
Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS (2010) 1.93
Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis (2002) 1.90
HIV infection in older patients in the HAART era. J Antimicrob Chemother (2005) 1.90
Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet (2011) 1.90
Observation plans in longitudinal studies with time-varying treatments. Stat Methods Med Res (2008) 1.89
Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol (2007) 1.87
Bivariate linear mixed models using SAS proc MIXED. Comput Methods Programs Biomed (2002) 1.87